Keytruda improves PFS in classical Hodgkin lymphoma
The drug went head-to-head with brentuximab vedotin (BV) – also sold as Adcetris by Seattle Genetics.
Read More
Tag: classical Hodgkin lymphoma
NICE backing for Keytruda in classical Hodgkin lymphoma
The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma.
Read More
NICE backs Opdivo for classical Hodgkin lymphoma
Patients with classical Hodgkin lymphoma (cHL) living in England and Wales could now become the first to get routine access on the NHS to Bristol-Myers Squibb’s immunotherapy Opdivo after a u-turn saw cost regulators provisionally back the drug.
Read More
MSD’s Keytruda closer to classical Hodgkin Lymphoma nod
MSD’s anti-PD-1 therapy Keytruda has taken a giant leap towards being approved in Europe for the treatment of classical Hodgkin Lymphoma (cHL).
Read More
NICE asks for more data on Opdivo
The National Institute for Health and Care Excellence has published draft guidelines recommending that Bristol Myers-Squibb provide more information on Opdivo’s effectiveness for treating classical Hodgkin lymphoma.
Read More
UK cHL patients get early access to Opdivo
UK patients with a certain form of blood cancer will get access to Bristol-Myers Squibb’s immunotherapy Opdivo through the Early Access to Medicines Scheme (EAMS), ahead of its European licence.
Read More
Trial shows high response rates for Merck’s Keytruda
An analysis of data from a Phase II study of Merck & Co’s immunotherapy Keytruda has demonstrated high response rates in heavily pre-treated patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
